scholarly journals Validation of the Eighth American Joint Committee on Cancer Anatomic and Prognostic Staging System for Breast Cancer

2022 ◽  
Vol 270 ◽  
pp. 539-546
Author(s):  
Pei-dong Yang ◽  
Qing-Qin Peng ◽  
Wei-bin Lian ◽  
Fang-meng Fu ◽  
Chuan Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Staging System ◽  
American Joint Committee ◽  
Prognostic Staging System

scholarly journals Prognostic and Predictive Value of the American Joint Committee on Cancer Pathological Prognostic Staging System in Nodal Micrometastatic Breast Cancer

2020 ◽  
Vol 10 ◽  
Author(s):  
Jian Shi ◽  
Chen-Lu Lian ◽  
Feng Chi ◽  
Ping Zhou ◽  
Jian Lei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Regression Model ◽  
Staging System ◽  
Cox Proportional Hazards ◽  
Breast Cancer Patients ◽  
Operating Characteristics ◽  
Cancer Specific Survival ◽  
Discriminative Ability ◽  
American Joint Committee ◽  
Prognostic Staging System

IntroductionTo investigate the prognostic and predictive effect of the American Joint Committee on Cancer (AJCC) 8th edition pathological prognostic staging system in patients with T1-2N1micM0 breast cancer who underwent mastectomy.MethodsData from T1-2N1micM0 breast cancer patients who underwent mastectomy from 2010–2014 were obtained from the Surveillance, Epidemiology, and End Results program. The chi-square test, binomial logistics regression, receiver-operating characteristics curve, competing-risk regression model, Cox proportional hazards regression model, and proportional hazard assumption were used for statistical analyses.ResultsWe identified 4,729 patients, including 1,062 patients were received postmastectomy radiotherapy (PMRT). Stage change occurred in 88.2% of the patients, of which 84.4% were downstaged and 3.7% were upstaged. Patients with higher pathological prognostic stages were independently predicted to receive PMRT. The 5-year breast cancer-specific survival (BCSS) was 97.5, 93.7, 90.1, 86.0, and 73.5% in disease stages IA, IB, IIA, IIB, and IIIA, respectively, according to the 8th edition criteria (P < 0.001). The AJCC 8th edition demonstrated moderate discriminative ability, and it had a significantly better ability to predict the BCSS than the AJCC 7th edition criteria (P < 0.001). The multivariate prognostic analysis showed that the new pathological prognostic staging was an independent prognostic factor affecting the BCSS. The BCSS worsened with an increase in the stage. The PMRT did not affect the BCSS regardless of the pathological prognostic stage. Similar trends were found using the competing-risks regression model.ConclusionsThe 8th AJCC breast cancer pathological prognostic staging system downstaged 84.4% of patients with T1-2N1micM0 disease and the survival outcome prediction with this staging system was more accurate than the AJCC 7th edition system. Our study does not support using the prognostic stage as a guideline to escalate of PMRT.

scholarly journals Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System

2017 ◽  
Vol 22 (11) ◽  
pp. 1292-1300 ◽  
Author(s):  
Mariana Chavez‐MacGregor ◽  
Elizabeth A. Mittendorf ◽  
Christina A. Clarke ◽  
Daphne Y. Lichtensztajn ◽  
Kelly K. Hunt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Tumor Characteristics ◽  
Breast Cancer Staging ◽  
Cancer Breast ◽  
American Joint Committee

Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer Dramatically Affect Stage-Specific Survival

2003 ◽  
Vol 21 (17) ◽  
pp. 3244-3248 ◽  
Author(s):  
Wendy A. Woodward ◽  
Eric A. Strom ◽  
Susan L. Tucker ◽  
Marsha D. McNeese ◽  
George H. Perkins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Strategies ◽  
Staging System ◽  
Stage Ii ◽  
Rank Test ◽  
Breast Cancer Patients ◽  
American Joint Committee ◽  
Number Of Patients ◽  
Ajcc Staging System ◽  
Ajcc Staging

Purpose: To evaluate how implementation of the 2003 American Joint Committee on Cancer (AJCC) staging system will affect stage-specific survival of breast cancer patients. Patients and Methods: Records of 1,350 patients treated on sequential institutional protocols with mastectomy and adjuvant doxorubicin-based chemotherapy were reviewed. Pathologic stage was assigned retrospectively according to the 1988 and the 2003 AJCC staging criteria. Overall stage-specific survival (OS) was calculated using the Kaplan-Meier method, and hypothetical differences were compared by the log-rank test. Results: Six hundred five of 1,087 patients with stage II disease according to the 1988 classification system had stage II disease according to the 2003 system. The 10-year OS for patients with stage II disease was significantly improved using the 2003 system (76% [2003] v 65% [1988]; P < .0001). Two hundred eighty-nine of 633 patients with stage IIb disease using the 1988 system were stage IIb with the 2003 system, and 10-year OS was 58% (1988) versus 70% (2003; P = .003). The number of patients with stage III disease increased from 207 (1988) to 443 (2003), and the 10-year OS changed from 45% (1988) to 50% (2003; P = .077). Most of this difference resulted from changes within stage IIIa: OS, 45% (1988) versus 59% (2003; P < .0001). Conclusion: Stage reclassification using the new AJCC staging system for breast cancer will result in significant changes in reported outcome by stage. It is imperative that careful attention is devoted to this effect so that accurate conclusions regarding the efficacy of new treatment strategies can be drawn.

Sign in / Sign up

Export Citation Format

Share Document